2026-11-02T11:45:42.000Z · 19 days ago ProMIS Neurosciences price target lowered to $15 from $29 at Roth Capital PMN
2026-10-30T15:40:14.000Z · 22 days ago Acumen downgraded to Underweight from Overweight at Cantor Fitzgerald
2026-10-30T11:05:34.000Z · 22 days ago Acumen reports ALTITUDE-AD clinical trial did not meet primary endpoint
Oct 30, 2026, 7:00 AM EDT · 22 days ago Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
Oct 26, 2026, 7:00 AM EDT · 26 days ago Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Oct 22, 2026, 7:30 AM EDT · 4 weeks ago Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
Oct 19, 2026, 4:00 PM EDT · 4 weeks ago Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Sep 10, 2026, 4:00 PM EDT · 2 months ago Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Sep 2, 2026, 4:00 PM EDT · 2 months ago Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 12, 2026, 7:00 AM EDT · 3 months ago Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 5, 2026, 4:00 PM EDT · 3 months ago Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
Jul 15, 2026, 7:30 AM EDT · 4 months ago Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
Jul 7, 2026, 7:30 AM EDT · 4 months ago Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026
Jun 17, 2026, 12:30 PM EDT · 5 months ago JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
Jun 16, 2026, 7:30 AM EDT · 5 months ago Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer's Disease
May 12, 2026, 7:00 AM EDT · 6 months ago Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
May 7, 2026, 4:00 PM EDT · 6 months ago Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 5, 2026, 4:00 PM EDT · 6 months ago Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
2026-03-26T20:35:57.000Z · 8 months ago Acumen files to sell 10.83M shares of common stock for holders
Mar 26, 2026, 7:00 AM EDT · 8 months ago Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Mar 19, 2026, 4:00 PM EDT · 8 months ago Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
2026-03-17T12:11:29.000Z · 8 months ago Acumen announces new research findings at Alzheimer’s and Parkinson’s conference
Mar 16, 2026, 6:30 AM EDT · 8 months ago Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
Mar 10, 2026, 4:00 PM EDT · 8 months ago Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Aug 12, 2025, 7:00 AM EDT · 1 year ago Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
Aug 5, 2025, 4:00 PM EDT · 1 year ago Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
Jul 15, 2025, 7:00 AM EDT · 1 year ago JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
Jul 10, 2025, 8:00 AM EDT · 1 year ago Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
May 7, 2025, 4:00 PM EDT · 1 year ago Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
May 6, 2025, 4:00 PM EDT · 1 year ago Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Apr 2, 2025, 7:00 AM EDT · 1 year ago Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Mar 20, 2025, 4:00 PM EDT · 1 year ago Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Mar 18, 2025, 8:48 AM EDT · 1 year ago Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
Mar 12, 2025, 8:00 AM EDT · 1 year ago Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Nov 26, 2024, 4:00 PM EST · 1 year ago Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Nov 11, 2024, 4:00 PM EST · 2 years ago Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Nov 6, 2024, 4:00 PM EST · 2 years ago Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Oct 31, 2024, 8:05 AM EDT · 2 years ago Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
Oct 23, 2024, 8:00 AM EDT · 2 years ago Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
Sep 30, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
Sep 25, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
Sep 3, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Aug 6, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
Jul 29, 2024, 7:00 AM EDT · 2 years ago Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease
Jul 28, 2024, 7:30 AM EDT · 2 years ago Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024
May 14, 2024, 7:00 AM EDT · 2 years ago Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 13, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 8, 2024, 5:47 PM EDT · 2 years ago Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 8, 2024, 8:00 AM EDT · 2 years ago Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
May 7, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
Apr 16, 2024, 8:00 AM EDT · 2 years ago Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Apr 4, 2024, 8:00 AM EDT · 2 years ago Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
Mar 26, 2024, 7:00 AM EDT · 2 years ago Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Mar 19, 2024, 4:00 PM EDT · 2 years ago Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024